Rilematovir
Small moleculeexperimental
Clinical trial activity
18 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
10
Phase 2
7
Phase 3
1
Phase 4
0
Earliest trial started Mar 1, 2015 (NCT02426632)
Timeline
Indications
Mechanism of action
- Respiratory syncytial virusINHIBITOR
Respiratory syncytial virus inhibitor
- Fusion glycoprotein F0INHIBITOR
Fusion glycoprotein F0 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CS(=O)(=O)CCCn1c(Cn2c(=O)n(CC(F)(F)F)c3ccncc32)cc2cc(Cl)ccc21- Mol. weight
- 500.93 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4437054 ↗
Also known as
- jnj 53718678
- jnj-53718678
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05155007 | Phase 1 | Dec 10, 2021 | Janssen Pharmaceutica NV |
| NCT04978337 | Phase 2 | Dec 1, 2021 | Janssen Pharmaceutica NV |
| NCT04583280 | Phase 3 | Sep 6, 2021 | Janssen Pharmaceutica NV |
| NCT04332523 | Phase 1 | Apr 13, 2020 | Janssen Pharmaceutica NV |
| NCT04056611 | Phase 2 | Oct 28, 2019 | Janssen Pharmaceutica NV |
| NCT04068792 | Phase 2 | Sep 27, 2019 | Janssen Pharmaceutica NV |
| NCT04090086 | Phase 1 | Sep 15, 2019 | Janssen Pharmaceutica NV |
| NCT03656510 | Phase 2 | Oct 8, 2018 | Janssen Pharmaceutica NV |
| NCT03696459 | Phase 1 | Oct 2, 2018 | Johnson and Johnson |
| NCT03379675 | Phase 2 | Feb 6, 2018 | Johnson and Johnson |
| NCT03002779 | Phase 1 | Jan 26, 2017 | Johnson and Johnson |
| NCT02945007 | Phase 1 | Nov 8, 2016 | Johnson and Johnson |
| NCT02729467 | Phase 1 | Mar 1, 2016 | Johnson and Johnson |
| NCT02593851 | Phase 1 | Dec 4, 2015 | Janssen Pharmaceutica NV, Johnson and Johnson |
| NCT02387606 | Phase 2 | May 1, 2015 | Janssen Pharmaceutica NV, Johnson and Johnson |
| NCT02398591 | Phase 1 | Apr 1, 2015 | Janssen Pharmaceutica NV, Johnson and Johnson |
| NCT02426632 | Phase 1 | Mar 1, 2015 | Janssen Pharmaceutica NV, Johnson and Johnson |
| NCT04221412 | N/A | — | Janssen Pharmaceutica NV |
Showing 18 of 18 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Janssen Pharmaceutica NV | For profit | 13 | 9 | 4 | 2015 |
| Johnson and Johnson | For profit | 9 | 9 | 2 | 2015 |
2 organizations
Page 1 / 1